Aggressive multiple sclerosis (1): Towards a definition of the phenotypeEllen Iacobaeus, Emmanuelle Waubant, Maria Pia Amato et al.|Multiple Sclerosis Journal|2020Cited by 79
Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotypeCatherine Milch, Joseph R. Berger, Tim Wyant et al.|Journal of Neuroimmunology|2013Cited by 77
Vedolizumab does not reduce the CD4+:CD8+ ratio in the CSF of healthy volunteersCatherine Milch, Irving H. Fox, Tim Wyant et al.|Inflammatory Bowel Diseases|2011Cited by 11
The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosisHelmut Butzkueven, Meritxell Sabidó, Jan Hillert et al.|Current Medical Research and Opinion|2023Cited by 7
A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical TrialsAsit Parikh, David B. Clifford, Kristin Stephens et al.|Drug Safety|2018Cited by 6